The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship of incomplete inhibition of PI3K pathway signaling and efficacy of cetuximab in KRAS wild-type colorectal cancers.
Ryan Bruce Corcoran
No relevant relationships to disclose
Hiromichi Ebi
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
Jeffrey A. Meyerhardt
No relevant relationships to disclose
Jeffrey A. Engelman
No relevant relationships to disclose